// App-Quantinova.ai

5506.0 : Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

Researchers

Presenter

  • Amir Goldkorn

Principal Investigators

  • Melissa Plets

  • Gareth Morrison

  • Alexander Cunha

  • Tong Xu

  • Jacek K. Pinski

  • Sue A. Ingles

  • Timothy Triche

  • Gary R. MacVicar

  • Daniel A. Vaena

  • Anthony W. Crispino

  • David James McConkey

  • Primo Lara

  • Maha H. A. Hussain

  • David I. Quinn

  • Nicholas J. Vogelzang

  • Ian Murchie Thompson

  • Neeraj Agarwal

Medical Centers

  • Division of Medical Oncology, Department of Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA

  • SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • University of Southern California, Los Angeles, CA

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, CA

  • Children's Hosp Los Angeles, Los Angeles, CA

  • Illinois CancerCare PC, Peoria, IL

  • University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA

  • SWOG and UsTOO Las Vegas, Las Vegas, NV

  • Johns Hopkins University Greenberg Bladder Cancer Institute, Baltimore, MD

  • University of California, San Francisco, CA

  • Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Christus Santa Rosa Hospital-Medical Center, San Antonio, TX

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Bicalutamide

  • Orteronel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved